Post A Reply
my profile
login
|
register
|
search
|
faq
|
forum home
»
Allstocks.com's Bulletin Board
»
Micro Penny Stocks, Penny Stocks $0.10 & Under
»
XKEM
» Post A Reply
Post A Reply
Login Name:
Password:
Message Icon:
Message:
HTML is not enabled.
UBB Code™ is enabled.
[QUOTE]Originally posted by bond006: [QB] A repost This is why I am in this long term OMG Look At this info on XKEM This is price target $4.16 According to Dr. Ramesh C. Pandey, Chairman & CEO of Xechem, "We are working hard to bring NICOSAN(TM) / HEMOXIN(TM) to market initially in Nigeria and subsequently in the United States and other countries. There are approximately 4,000,000 people afflicted with Sickle Cell Disease in Nigeria alone, and development of this product is a major initiative of the Nigerian government, which has shown tremendous support for our efforts. The Nigerian market alone represents potential revenue in excess of $500,000,000 for the company. Xechem was prominently mentioned several times in the state of the union address by the Nigerian President late in 2004.Basically He states that Just in Nigeria the market is worth over $500 million in revenue alone per year. We figure that within a year they will have the production facilities active to supply all of Nigeria with the drug. Now considering he was able to give us a Revenue projection, all we need now was to compare this to other BioTech companies, by their Price to sales (Revenue) ratios. Lets do the math......... Company Name Price to Sales Ratio Amgen: 16.40 (Averages between 5-17 in the last 5 years) Genetech 11.32 Acadia Pharmaceuticals 21.3 Biomira Inc 26.1 In General the Price to sales ratios tended to run between 2-30 averaging around 10 on the 20 random BioTechnology companies we looked at. Now Lets use the average of 10 and multiply that by the Projected revenue figure given to us by Dr. Pandey once the drug is supplied to only Nigeria: $500 million X 10 = $5 billion market cap 5,000,000,000 / 1,200,000,000 = Share price of: $4.16 (1 year projection) Now understand that Nigeria represents just 1/3 of the worlds sickle cell anemia sufferers. Now it will take them longer to get their product approved and distruibuted to the rest of the world, however this should be able to be accomplished in a 3-5 year timespan. Given the numbers above we get: 3 X 5,000,000,000 / 1,200,000,000 = Share Price of: $12.48 ( 3-5 year projection) As you can see this company is going to be tremendously undervalued once the Drug approval PR and Launch of the drug takes place. Stock Alert! = Xechem International Inc. Ticker Symbol = XKEM Sector:Healthcare Industry: Biotechnology Website = [URL=http://www.xechem.com]www.xechem.com[/URL] Short Term Target Price = $4.16 Long Term Target Price = $12.48 Disclosure = We Own Shares Recommendation = MEGA BONUS BUY !!! Information To Consider 1.Nigeria Export Import Bank (NEXIM) has concluded plans to raise its share capital from N50 billion to N100 billion. This is coming at a time when President Olusegun Obasanjo gave the management and board of the bank, a part on the back for a job well done. The bank recently concluded a deal to fund a drug, NICOSAN, which would generate a yearly minimum of $5 million in foreign exchange in the first two years of operations from royalty payments and exports. 2.Nigeria has broken new grounds in biotechnology with the production of a drug which effectively controls the sickle cell anemia. The drug named NICOSAM would be officially launched on July 8 by the President, Chief Olusegun Obasanjo. According to the Minister of Science and Technology, Prof. Turner Isoun, the drug would also be exported to other countries of the world. 3.On June 15, 2006, Xechem International, Inc. reached final agreement with Marjorie Chassman ("Chassman") regarding a bridge loan financing, whereby Chassman agrees to loan $1,025,000 to Xechem, in two tranches, one in the amount of $500,000 and the other in the amount of $525,000. The first tranche of $500,000 was infused on Friday, June 9, 2006. The second tranche of $525,000 is due by Friday, June 23, 2006. The note has been negotiated to convert into shares of our common stock at $0.015 per share (approximately 66,666,667 shares, excluding interest). The note bears interest at 8% and is due May 31, 2008. As additional consideration for infusion of the capital, Xechem will issue Chassman 66,666,667 warrants, exercisable at $0.02 per share for a period of 5 years. In addition, Chassman has agreed to extend the due date on all existing notes held by the Company to May 31, 2008. The loan has not been documented at this time. Upon documentation, it will be filed as an exhibit . 3.NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--June 6, 2006--Xechem International, Inc. (OTC BB: XKEM - News) Xechem International announced today that it has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA), Office of Orphan Drug Products Development, for the five-membered heterocyclic anti-sickling compound known as 5-HMF for the treatment of patients suffering from sickle cell disease (SCD). 4.NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--June 1, 2006--Xechem International, Inc. (OTC BB: XKEM - News) announced today that its Nigerian subsidiary, Xechem Pharmaceuticals Nigeria Ltd. (Xechem Nigeria), has successfully closed on a N150 Million Naira ($1.2 million) loan from the Nigerian Export-Import (NEXIM) Bank. The loan has a three year term, with a moratorium on repayment of principal during the first year. Xechem International is neither a borrower nor a guarantor under the loan facility in this transaction. 5.NEW BRUNSWICK, NJ – January 25, 2006 – Xechem International, Inc. (OTC BB: XKEM) Xechem International said today that the $4.2 million settlement of its antitrust lawsuit against Bristol-Meyers Squibb Co., announced December 2005, has closed and that the net settlement proceeds have now been received by the company. 6.RE: Nicosan VS Hydroxyurea Nicosan: no none side effects Hydroxyurea: IMPORTANT WARNING: Hydroxyurea may cause severe, life-threatening side effects, including certain cancers. Talk to your doctor about the risks of using hydroxyurea for your condition. [/QB][/QUOTE]
Instant Graemlins
Instant UBB Code™
What is UBB Code™?
Options
Disable Graemlins in this post.
*** Click here to review this topic. ***
Contact Us
|
Allstocks.com Message Board Home
© 1997 - 2021 Allstocks.com. All rights reserved.
Powered by
Infopop Corporation
UBB.classic™ 6.7.2